Implementation of proteomic biomarkers: making it work

Eur J Clin Invest 2012; 42 (9): 1027–1036

[1]  N. Sattar.  Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[2]  John P A Ioannidis,et al.  Improving Validation Practices in “Omics” Research , 2011, Science.

[3]  B. Keogh.  European biobanks forge cross-border ties. , 2011, Journal of the National Cancer Institute.

[4]  M. Waldenberger,et al.  Comprehensive catalog of European biobanks , 2011, Nature Biotechnology.

[5]  Jane Kaye,et al.  From single biobanks to international networks: developing e-governance , 2011, Human Genetics.

[6]  Paul R. Burton,et al.  Realizing the promise of population biobanks: a new model for translation , 2011, Human Genetics.

[7]  Richard Z. Liu,et al.  A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer , 2011, Proteomics. Clinical applications.

[8]  J. Ioannidis,et al.  Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. , 2011, JAMA.

[9]  A. Vlahou,et al.  Urine proteomics in kidney and urogenital diseases: Moving towards clinical applications , 2011, Proteomics. Clinical applications.

[10]  J. Ioannidis.  A roadmap for successful applications of clinical proteomics , 2011, Proteomics. Clinical applications.

[11]  Efthymios Manolis,et al.  New pathway for qualification of novel methodologies in the European medicines agency , 2011, Proteomics. Clinical applications.

[12]  A. Ortiz,et al.  Proteomics in chronic kidney disease: The issues clinical nephrologists need an answer for , 2011, Proteomics. Clinical applications.

[13]  Igor Rudan,et al.  Ethical aspects of human biobanks: a systematic review , 2011, Croatian medical journal.

[14]  R. J. Cadigan,et al.  Genomics, Biobanks, and the Trade-Secret Model , 2011, Science.

[15]  Henry Rodriguez,et al.  The journey to regulation of protein-based multiplex quantitative assays. , 2011, Clinical chemistry.

[16]  L. Ruilope,et al.  Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.

[17]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[18]  A. Dispenzieri,et al.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[19]  J. Sanne,et al.  Basic and clinical proteomics from the EU Health Research perspective , 2010, Proteomics. Clinical applications.

[20]  E. Diamandis,et al.  Cancer biomarkers: can we turn recent failures into success? , 2010, Journal of the National Cancer Institute.

[21]  H. Mischak,et al.  Proteomic biomarkers in diabetic nephropathy--reality or future promise? , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  M. Girolami,et al.  Recommendations for Biomarker Identification and Qualification in Clinical Proteomics , 2010, Science Translational Medicine.

[23]  M. Girolami,et al.  Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease* , 2010, Molecular & Cellular Proteomics.

[24]  James H. Doroshow,et al.  AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development , 2010, Clinical Cancer Research.

[25]  John P A Ioannidis,et al.  What makes a good predictor?: the evidence applied to coronary artery calcium score. , 2010, JAMA.

[26]  N. Anderson,et al.  The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. , 2010, Clinical chemistry.

[27]  M. Khoury,et al.  Personal genomics: information can be harmful , 2010, European journal of clinical investigation.

[28]  D. Bild,et al.  Score What Makes a Good Predictor ? : The Evidence Applied to Coronary Artery Calcium , 2010 .

[29]  B. Rovin,et al.  Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. , 2009, Journal of the American Society of Nephrology : JASN.

[30]  H. Parving,et al.  Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. , 2009, Annals of internal medicine.

[31]  Harald Mischak,et al.  Identification and Validation of Urinary Biomarkers for Differential Diagnosis and Evaluation of Therapeutic Intervention in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis* , 2009, Molecular & Cellular Proteomics.

[32]  M. Knepper.  Common sense approaches to urinary biomarker study design. , 2009, Journal of the American Society of Nephrology : JASN.

[33]  Jean W. Lee,et al.  Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  Brian L Hood,et al.  Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation. , 2009, Clinics in laboratory medicine.

[35]  R. Klein,et al.  Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials , 2008, The Lancet.

[36]  H. Parving,et al.  Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial , 2008, The Lancet.

[37]  William D. Figg,et al.  Validation of Analytic Methods for Biomarkers Used in Drug Development , 2008, Clinical Cancer Research.

[38]  Jessie Venegas.  Department of Hygiene and Epidemiology, University of Ioannina School of Medicine , 2008 .

[39]  Anushka Patel,et al.  Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial , 2007, The Lancet.

[40]  M. Girolami,et al.  Clinical proteomics: A need to define the field and to begin to set adequate standards , 2007, Proteomics. Clinical applications.

[41]  Steven A Carr,et al.  Protein biomarker discovery and validation: the long and uncertain path to clinical utility , 2006, Nature Biotechnology.

[42]  M. Mauer,et al.  Preventing microalbuminuria in type 2 diabetes. , 2005, The New England journal of medicine.

[43]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[44]  S M Hanash,et al.  Proteomic Approaches within the NCI Early Detection Research Network for the Discovery and Identification of Cancer Biomarkers , 2001, Annals of the New York Academy of Sciences.

[45]  S. Yusuf,et al.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[46]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.